Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.300
+0.010 (0.44%)
At close: Oct 28, 2025, 4:00 PM EDT
2.350
+0.050 (2.17%)
After-hours: Oct 28, 2025, 7:59 PM EDT
Cardiff Oncology Revenue
Cardiff Oncology had revenue of $121.00K in the quarter ending June 30, 2025, a decrease of -25.77%. This brings the company's revenue in the last twelve months to $545.00K, down -18.05% year-over-year. In the year 2024, Cardiff Oncology had annual revenue of $683.00K with 39.96% growth.
Revenue (ttm)
$545.00K
Revenue Growth
-18.05%
P/S Ratio
247.05
Revenue / Employee
$16,515
Employees
33
Market Cap
153.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 683.00K | 195.00K | 39.96% |
| Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
| Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
| Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
| Dec 31, 2020 | 366.00K | 121.37K | 49.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CRDF News
- 3 days ago - Cardiff Oncology: Preparing For A Defining 2026 - Seeking Alpha
- 6 days ago - Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy - Seeking Alpha
- 26 days ago - Cardiff Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - Benzinga
- 3 months ago - Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
- 3 months ago - Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) - GlobeNewsWire
- 4 months ago - Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha